Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ACR | P10323 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055418 | 0.87 | ADORA1 (0.47) | ADORA1ADORA3ADORA2AADORA2BACR | |
| SCHEMBL4058704 | 0.84 | ADORA1 (0.48) | ADORA1ADORA3ADORA2AADORA2BACR | |
| SCHEMBL4065583 | 0.83 | ADORA3 (0.46) | ADORA1ADORA3ADORA2AADORA2BACR | |
| SCHEMBL4062416 | 0.82 | PSEN1 (0.46) | ADORA1ADORA3ADORA2AADORA2BACR | |
| SCHEMBL4058155 | 0.82 | ADORA3 (0.45) | ADORA1ADORA3ADORA2AADORA2BACR | |
| SCHEMBL4060451 | 0.81 | ADORA3 (0.48) | ADORA1ADORA3ADORA2AADORA2BACR | |
| SCHEMBL4054820 | 0.81 | ADORA3 (0.50) | ADORA1ADORA3ADORA2AADORA2BACR | |
| SCHEMBL4057092 | 0.80 | ADORA3 (0.42) | ADORA1ADORA3ADORA2AADORA2BACR | |
| SCHEMBL8312713 | 0.80 | MMP1 (0.35) | ADORA1ADORA3ADORA2AADORA2BMAPK14 | |
| SCHEMBL5489292 | 0.80 | MMP1 (0.35) | ADORA1ADORA3ADORA2AADORA2BMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | claimed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| US-7521464-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-7238721-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | APP, PARK7, BACE1 | ADORA1 16/4885ADORA3 30/4885ADORA2A 357/4885 |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | APP, BACE1, PSEN1 | ADORA1 27/4885ADORA3 97/4885ADORA2A 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.